☆ 4.6 Article

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

CELL REPORTS MEDICINE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Multidisciplinary Sciences

Spike mutation D614G alters SARS-CoV-2 fitness

Jessica A. Plante et al.

Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.

NATURE (2021)

添加到收藏夹

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Microbiology

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Drew Weissman et al.

Summary: The D614G mutation in the spike protein of SARS-CoV-2 is not expected to hinder current vaccine development, as viruses with the G614 spike are more susceptible to neutralization, indicating that the mutation may not affect vaccine efficacy.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler et al.

Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

添加到收藏夹

Letter Virology

Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil

Carolina M. Voloch et al.

JOURNAL OF VIROLOGY (2021)

添加到收藏夹

Review Infectious Diseases

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Susanne H. Hodgson et al.

Summary: The development of a vaccine for the novel coronavirus is crucial to prevent the spread of the pandemic and reduce disease mortality. The efficacy endpoint is protection against severe disease and death, but evaluating this in phase 3 clinical trials poses challenges.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp et al.

Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination

[Anonymous]

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Xiaoying Shen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Jingyou Yu et al.

Summary: The Ad26.COV2.S vaccine provides robust protection against the B.1.351 variant in rhesus macaques, despite generating lower neutralizing antibodies against B.1.351 compared to the WA1/2020 strain.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter et al.

Summary: The Ad26.COV2.S vaccine has shown clinical efficacy against symptomatic COVID-19, including the B.1.351 variant, but there is uncertainty regarding its immunogenicity against SARS-CoV-2 variants. The study found that neutralizing antibody responses were reduced against the B.1.351 and P.1 variants, while non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

添加到收藏夹

Review Immunology

Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies

Hanalise Huff et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Editorial Material Immunology

Respiratory Virus Infections: Understanding COVID-19

Kanta Subbarao et al.

IMMUNITY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Abishek Chandrashekar et al.

SCIENCE (2020)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

A strategic approach to COVID-19 vaccine R&D

Lawrence Corey et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu et al.

SCIENCE (2020)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village

Michael Day

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Anesthesiology

Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience

Lingzhong Meng et al.

ANESTHESIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Tyler N. Starr et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

添加到收藏夹

Article Immunology

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Caroline Atyeo et al.

IMMUNITY (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Gregory A. Poland et al.

LANCET (2020)

添加到收藏夹

News Item Multidisciplinary Sciences

MAKING SENSE OF CORONAVIRUS MUTATIONS

Ewen Callaway

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

M. Alejandra Tortorici et al.

SCIENCE (2020)

添加到收藏夹

Article Immunology

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre-Xabier et al.

VACCINE (2020)

添加到收藏夹

Article Microbiology

Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity

Carolin Loos et al.

MSPHERE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Tomer Zohar et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Lizhou Zhang et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: What have we learnt about the new variant in the UK?

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

添加到收藏夹

Review Immunology

The role of IgG Fc receptors in antibody-dependent enhancement

Stylianos Bournazos et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹

Article Biochemical Research Methods

A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis

Christina B. Karsten et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2019)

添加到收藏夹

Article Biochemical Research Methods

A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation

Stephanie Fischinger et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2019)

添加到收藏夹

Review Immunology

Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function

Andrew R. Crowley et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

A Sample-Sparing Multiplexed ADCP Assay

Audrey L. Butler et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Microbiology

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

Bronwyn M. Gunn et al.

CELL HOST & MICROBE (2018)

添加到收藏夹

Review Immunology

Diversification of IgG effector functions

Stylianos Bournazos et al.

INTERNATIONAL IMMUNOLOGY (2017)

添加到收藏夹

Article Biochemical Research Methods

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles

Eric P. Brown et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2017)

添加到收藏夹

Review Immunology

Early local immune defences in the respiratory tract

Akiko Iwasaki et al.

NATURE REVIEWS IMMUNOLOGY (2017)

添加到收藏夹

Article Immunology

Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners

Robert E. Sealy et al.

INTERNATIONAL IMMUNOLOGY (2016)

添加到收藏夹

Review Immunology

Fcγ receptor pathways during active and passive immunization

Stylianos Bournazos et al.

IMMUNOLOGICAL REVIEWS (2015)

添加到收藏夹

Review Immunology

Antiviral B cell and T cell immunity in the lungs

Christopher Chiu et al.

NATURE IMMUNOLOGY (2015)

添加到收藏夹

Article Allergy

B-lymphocyte lineage cells and the respiratory system

Atsushi Kato et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)

添加到收藏夹

Article Biochemical Research Methods

High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples

Eric P. Brown et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2012)

添加到收藏夹

Review Immunology

Fc gamma receptors as regulators of immune responses

Falk Nimmerjahn et al.

NATURE REVIEWS IMMUNOLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.